GlobalData

Oncology accounts for 30 per cent of all active CRISPR drugs

There are 694 CGTs in development across various therapy areas in the US as of February 2024

Among the comorbidities associated with ADHD, key opinion leaders (KOLs) interviewed by GlobalData noted anxiety disorder,…

Nezglyal is a novel orally bioavailable and selective peroxisome proliferator-activated receptor (PPAR) gamma agonist that is…

To address the clinical deficiencies stated in the CRL, Minerva must provide additional safety and efficacy data for roluperidone…

Takeda entered into multiple cell therapy collaborations for the development of CAR-T therapies with organizations like Memorial…

GlobalData estimates the drug to earn $3.12 billion by 2029

The focus is on introducing new molecular entities (NMEs) into India, with both parties contributing to accelerate…

Four companies – Lilly (59.2 per cent), Novo Nordisk (51.5 per cent), Vertex Pharmaceuticals (41.4 per cent) and Regeneron…

Praluent (alirocumab) is a monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), an enzyme that…